Multi-omics-driven biomarker discovery in autoimmune diseases: a comprehensive review

Autoimmune diseases (ADs) exhibit complex heterogeneity and dynamic pathological mechanisms. Traditional biomarkers face numerous challenges in the diagnosis and treatment of ADs. However, the rapid development of multi-omics technologies and bioinformatics has not only deepened the understanding of the pathogenesis of ADs but also identified many novel diagnostic and therapeutic biomarkers with good diagnostic performance. These biomarkers are now beginning to overcome these limitations. This review systematically explores the discovery of novel biomarkers driven by multi-omics technologies such as genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiomics, in response to the limitations of traditional biomarkers. It emphasises the significant importance of discovering novel biomarkers through multi-omics in the diagnosis and treatment of ADs, and proposes a concept from omics analysis to solving clinical problems, providing new directions for the diagnosis and treatment of ADs.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2025-12-08
DOI
https://doi.org/10.3389/fimmu.2025.1652211
Citations
3
Primary Topic
Diabetes and associated disorders
Type
article
Field-Weighted Citation Impact
5.45
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multi-omics-driven biomarker discovery in autoimmune diseases: a comprehensive review

Shasha Jiang, Heping Zhao, Haofeng Xu, Lijuan Xu et al.
3 citations
Frontiers in Immunology
Diabetes and associated disorders
5.45
article

Multi-omics-driven biomarker discovery in autoimmune diseases: a comprehensive review

Shasha Jiang, Heping Zhao, Haofeng Xu, Lijuan Xu, Yan Yu, Yi Zhang
article en
3 citations

Abstract

Autoimmune diseases (ADs) exhibit complex heterogeneity and dynamic pathological mechanisms. Traditional biomarkers face numerous challenges in the diagnosis and treatment of ADs. However, the rapid development of multi-omics technologies and bioinformatics has not only deepened the understanding of the pathogenesis of ADs but also identified many novel diagnostic and therapeutic biomarkers with good diagnostic performance. These biomarkers are now beginning to overcome these limitations. This review systematically explores the discovery of novel biomarkers driven by multi-omics technologies such as genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiomics, in response to the limitations of traditional biomarkers. It emphasises the significant importance of discovering novel biomarkers through multi-omics in the diagnosis and treatment of ADs, and proposes a concept from omics analysis to solving clinical problems, providing new directions for the diagnosis and treatment of ADs.

Frontiers in ImmunologyVol. 16
Xi'an Honghui Hospital (CN)
Openalex Percentile: Top 4%
Diabetes and associated disorders
5.45
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.